Literature DB >> 26282696

Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?

Hanna van Waart1, Wim H van Harten1, Laurien M Buffart2, Gabe S Sonke3, Martijn M Stuiver4, Neil K Aaronson1.   

Abstract

OBJECTIVE: Only between 25% and 50% of patients invited to participate in clinical trial-based physical exercise programs during cancer treatment agree to do so. The purpose of this study was to identify factors associated significantly with the decision (not) to participate in a randomized controlled trial of physical exercise during adjuvant chemotherapy for breast cancer.
METHODS: Based on questionnaire data, we compared trial participants and non-participants on a range of sociodemographic, clinical health-related, practical, behavioral, and attitudinal variables.
RESULTS: Two hundred thirty of 524 patients agreed to participate in the trial (44%). The 294 (56%) non-participants indicated that they wanted to exercise on their own or that they did not wish to exercise in the context of a trial. Those who preferred to exercise on their own were relatively similar to trial participants but were more likely to be in the maintenance exercise stage. Those non-participants who did not wish to exercise had a significantly lower level of education, were less likely to be working, reported more fatigue and lower health-related quality of life, had lower sense of self-efficacy, more negative attitudes towards exercise, less social support, and perceived fewer benefits and more barriers to exercising during treatment than trial participants.
CONCLUSION: Minimizing practical barriers to participation, providing educational materials on the potential benefits of exercise, and giving adequate professional and social network encouragement may increase the number of patients willing to exercise during treatment and to participate in such studies.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26282696     DOI: 10.1002/pon.3936

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  28 in total

1.  Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.

Authors:  Jennifer Huberty; Ryan Eckert; Krisstina Gowin; Jules Mitchell; Amylou C Dueck; Brenda F Ginos; Linda Larkey; Ruben Mesa
Journal:  Haematologica       Date:  2017-06-08       Impact factor: 9.941

Review 2.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

3.  Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer.

Authors:  Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson
Journal:  Int J Colorectal Dis       Date:  2017-11-09       Impact factor: 2.571

4.  Are patient-reported outcomes of physical function a valid substitute for objective measurements?

Authors:  J A J Douma; H M W Verheul; L M Buffart
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

5.  The association between fatigue and pain symptoms and decreased physical activity after cancer.

Authors:  Sally A D Romero; Lee Jones; Joshua M Bauml; Q Susan Li; Roger B Cohen; Jun J Mao
Journal:  Support Care Cancer       Date:  2018-04-19       Impact factor: 3.603

6.  Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.

Authors:  Hanna van Waart; Laurien M Buffart; Martijn M Stuiver; Wim H van Harten; Gabe S Sonke; Neil K Aaronson
Journal:  Support Care Cancer       Date:  2019-08-08       Impact factor: 3.603

7.  Insomnia as an Unmet Need in Patients With Chronic Hematological Cancer: Protocol for a Randomized Controlled Trial Evaluating a Consumer-Based Meditation App for Treatment of Sleep Disturbance.

Authors:  Jennifer Huberty; Nishat Bhuiyan; Ryan Eckert; Linda Larkey; Megan Petrov; Michael Todd; Ruben Mesa
Journal:  JMIR Res Protoc       Date:  2022-07-01

8.  A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.

Authors:  Heather S L Jim; Aasha I Hoogland; Hyo Sook Han; Eva Culakova; Charles Heckler; Michelle Janelsins; Geoffrey C Williams; Julienne Bower; Stephen Cole; Zeruesenay Desta; Margarita Bobonis Babilonia; Gary Morrow; Luke Peppone
Journal:  Contemp Clin Trials       Date:  2020-03-05       Impact factor: 2.226

9.  Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.

Authors:  Laurien M Buffart; Maike G Sweegers; Anne M May; Mai J Chinapaw; Jonna K van Vulpen; Rob U Newton; Daniel A Galvão; Neil K Aaronson; Martijn M Stuiver; Paul B Jacobsen; Irma M Verdonck-de Leeuw; Karen Steindorf; Melinda L Irwin; Sandi Hayes; Kathleen A Griffith; Alejandro Lucia; Fernando Herrero-Roman; Ilse Mesters; Ellen van Weert; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Gill Arbane; Martina E Schmidt; Karin Potthoff; Marc van Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H van Harten; Rachel Garrod; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem van Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Johannes Brug; Kerry S Courneya
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

10.  Obese Breast Cancer Patients and Survivors: Management Considerations.

Authors:  Jennifer Y Sheng; Dipali Sharma; Gerald Jerome; Cesar Augusto Santa-Maria
Journal:  Oncology (Williston Park)       Date:  2018-08-15       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.